Lucid Diagnostics Partners with ECAN to Highlight Esophageal Cancer Awareness Month

Commercial-stage cancer prevention company, Lucid Diagnostics Inc. (Nasdaq: LUCD) will partner with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. Together, the organizations aim to spread the potentially life-saving message that heartburn (also known as acid reflux or GERD) can lead to highly lethal esophageal cancer and that esophageal cancer is preventable through early precancer detection. Public service videos encouraging those at risk to get tested have been running on the iconic Nasdaq billboard in New York City’s Times Square as part of Esophageal Cancer Awareness Month. The company’s share price settled up nearly 10% on Monday following the news.

Esophageal cancer is one of the most malignant cancers and is responsible for the deaths of more than 16,000 Americans each year.

Shaun O’Neil, Lucid’s President and Chief Operating Officer, said, “Public awareness of the link between esophageal cancer and heartburn, as well as the fact that it can be prevented through early precancer detection, is lacking. At Lucid Diagnostics, we are proud of our long-standing collaboration with Mindy Mintz Mordecai and the ECAN team. ECAN has been a critical voice supporting our efforts to expand patient access to early precancer detection using EsoGuard.”

Lucid’s EsoGuard is a DNA test that has been shown to accurately detect esophageal precancer.

ECAN is a leading patient advocacy organization focused on increasing esophageal cancer education, advocacy, awareness, and research.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device – the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.